Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26


Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1.

Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandey A, Semenza GL.

Cell. 2011 May 27;145(5):732-44. doi: 10.1016/j.cell.2011.03.054.


Otto Warburg's contributions to current concepts of cancer metabolism.

Koppenol WH, Bounds PL, Dang CV.

Nat Rev Cancer. 2011 May;11(5):325-37. doi: 10.1038/nrc3038. Epub 2011 Apr 14. Review. Erratum in: Nat Rev Cancer. 2011 Aug;11(8):618.


Regulation of cancer cell metabolism.

Cairns RA, Harris IS, Mak TW.

Nat Rev Cancer. 2011 Feb;11(2):85-95. doi: 10.1038/nrc2981. Review.


Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.

Wykosky J, Fenton T, Furnari F, Cavenee WK.

Chin J Cancer. 2011 Jan;30(1):5-12. Review.


Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells.

Mazurek S.

Int J Biochem Cell Biol. 2011 Jul;43(7):969-80. doi: 10.1016/j.biocel.2010.02.005. Epub 2010 Feb 13. Review.


EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin.

Ji H, Wang J, Nika H, Hawke D, Keezer S, Ge Q, Fang B, Fang X, Fang D, Litchfield DW, Aldape K, Lu Z.

Mol Cell. 2009 Nov 25;36(4):547-59. doi: 10.1016/j.molcel.2009.09.034.


Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.

Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE, Daemen A, Bleeker FE, Bralten LB, Kloosterhof NK, De Moor B, Eilers PH, van der Spek PJ, Kros JM, Sillevis Smitt PA, van den Bent MJ, French PJ.

Cancer Res. 2009 Dec 1;69(23):9065-72. doi: 10.1158/0008-5472.CAN-09-2307. Epub 2009 Nov 17.


Understanding the Warburg effect: the metabolic requirements of cell proliferation.

Vander Heiden MG, Cantley LC, Thompson CB.

Science. 2009 May 22;324(5930):1029-33. doi: 10.1126/science.1160809. Review.


Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data.

Petalidis LP, Oulas A, Backlund M, Wayland MT, Liu L, Plant K, Happerfield L, Freeman TC, Poirazi P, Collins VP.

Mol Cancer Ther. 2008 May;7(5):1013-24. doi: 10.1158/1535-7163.MCT-07-0177. Epub 2008 Apr 29.


The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth.

Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC.

Nature. 2008 Mar 13;452(7184):230-3. doi: 10.1038/nature06734.


Pyruvate kinase M2 is a phosphotyrosine-binding protein.

Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC.

Nature. 2008 Mar 13;452(7184):181-6. doi: 10.1038/nature06667.


Malignant astrocytic glioma: genetics, biology, and paths to treatment.

Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK.

Genes Dev. 2007 Nov 1;21(21):2683-710. Review.


Serial analysis of chromatin occupancy identifies beta-catenin target genes in colorectal carcinoma cells.

Yochum GS, McWeeney S, Rajaraman V, Cleland R, Peters S, Goodman RH.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3324-9. Epub 2007 Feb 21.


Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.

Coluccia AM, Vacca A, Duñach M, Mologni L, Redaelli S, Bustos VH, Benati D, Pinna LA, Gambacorti-Passerini C.

EMBO J. 2007 Mar 7;26(5):1456-66. Epub 2007 Feb 22.


Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity.

Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T, Lu Z.

J Biol Chem. 2007 Apr 13;282(15):11221-9. Epub 2007 Feb 7.


c-Jun downregulation by HDAC3-dependent transcriptional repression promotes osmotic stress-induced cell apoptosis.

Xia Y, Wang J, Liu TJ, Yung WK, Hunter T, Lu Z.

Mol Cell. 2007 Jan 26;25(2):219-32.


Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K.

Cancer Cell. 2006 Mar;9(3):157-73.


Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.

Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J.

Clin Cancer Res. 2006 Jan 15;12(2):556-62.


Gene expression profiling of gliomas strongly predicts survival.

Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF.

Cancer Res. 2004 Sep 15;64(18):6503-10.


Wnt-independent beta-catenin transactivation in tumor development.

Lu Z, Hunter T.

Cell Cycle. 2004 May;3(5):571-3. Epub 2004 May 25.


Supplemental Content

Support Center